Deal with NewBridge Allows Genomic Health to Expand Oncotype DX into Africa, Middle East | GenomeWeb

NEW YORK (GenomeWeb News) – An exclusive agreement with NewBridge Pharmaceuticals will enable molecular diagnostics firm Genomic Health to expand the market for its flagship breast and colon cancer recurrence test Oncotype DX into Africa, the Middle East, and surrounding regions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.